Category Archives: Biotech

The US Biotech Drug Pricing Challenge

by Tom Norton In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology.  According to the New York Times: “One of the most heavily reimbursed procedures — costing a […]
Also posted in Corporate Responsibility, Guest Blog, healthcare, Market Access, pricing, Strategy | Tagged , , , , , , , , | 1 Comment

Biopharmaceuticals: Approvals Rate Best in Five Years

Overall, last year can be considered quite a successful one in terms of new product approvals. Nineteen products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. These approval numbers are above average compared to the previous five years, which recorded a mean approval rate of 13 products. The […]
Also posted in Europe, Global, Guest Blog, Regulatory | Tagged , , | Leave a comment

After Delays, Project DataSphere Rolls Out

An industry and academic data-sharing project went live on Tuesday, nearly a year after the platform was expected to launch. Visitors to the site – no credentials needed – can register and access de-identified clinical data from the comparator arms of nine oncology trials, with more to come. Project DataSphere, the newest data transparency and […]
Also posted in Corporate Responsibility, Europe, FDA, Global, IP, leadership, Legal, R&D, Strategy, Technology | Tagged , , , , , , , , , | Leave a comment

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Also posted in healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Tagged , , , , , , , , , | 1 Comment

Baxter Splits Biopharm and Medical Products into Two Businesses

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.
Also posted in Strategy | Tagged , , | Leave a comment
  • Categories

  • Meta